Skip to main content

Advertisement

SpringerLink
Log in

Utilization of FibroScan in Clinical Practice

  • Liver (B Bacon, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

The evaluation of liver fibrosis is critical, particularly to rule out cirrhosis. Novel non-invasive tests such as transient ultrasound elastography are widely used to stage liver fibrosis as an alternative to liver biopsy, and this technology has recently been approved in the US. In this review, we discuss the performance characteristics of elastography for a variety of liver diseases and highlight practical appropriate suggestions for how to incorporate this technology into clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017–44.

    Article  PubMed  Google Scholar 

  2. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134(6):1670–8.

    Article  CAS  PubMed  Google Scholar 

  3. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–13.

    Article  PubMed  Google Scholar 

  4. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828–35. A high BMI and obesity are factors that are associated with inaccurate LSM measurements.

    PubMed  Google Scholar 

  5. Foucher J, Castera L, Bernard PH, et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol. 2006;18:411–2.

    Article  PubMed  Google Scholar 

  6. de Lédinghen V, Vergniol J, Foucher J, et al. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010;30:1043–8.

    Article  PubMed  Google Scholar 

  7. Friedrich-Rust M, Hadji-Hosseini H, Kriener S, et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol. 2010;20:2390–6.

    Article  PubMed  Google Scholar 

  8. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107:1862–71. The XL probe is an important tool for patients with obesity and high BMI for accurate LSM measurements.

    Article  PubMed  Google Scholar 

  9. Pradhan F, Ladak F, Tracey J, et al. Feasibility and reliability of the FibroScan S2 (pediatric) probe compared with the M probe for liver stiffness measurement in small adults with chronic liver disease. Ann Hepatol. 2013;12:100–7.

    PubMed  Google Scholar 

  10. Colli A, Pozzoni P, Berzuini A, et al. Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography. Radiology. 2010;3:872–8.

    Article  Google Scholar 

  11. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008;47:380–4.

    Article  CAS  PubMed  Google Scholar 

  12. Sagir A, Erhardt A, Schmitt M, et al. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology. 2008;47:592–5.

    Article  CAS  PubMed  Google Scholar 

  13. Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 2008;48:1718–23.

    Article  PubMed  Google Scholar 

  14. Tapper EB, Cohen EB, Patel K, et al. Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2012;10:932–7. Elevated liver tests in patients with early stage fibrosis may cause an increase in LSM measurements and should be considered as a variable that can falsely raise liver stiffness.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. de Lédinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–8. CAP with transient elastography is an accurate mode of measurement of liver steatosis and represents a novel additional benefit of the technology.

    Article  PubMed  Google Scholar 

  16. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;1:167–85.

    Google Scholar 

  17. Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47:760–7.

    Article  CAS  PubMed  Google Scholar 

  18. Cardoso AC, Carvalho-Filho RJ, Stern C, et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int. 2012;32:612–21.

    Article  CAS  PubMed  Google Scholar 

  19. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41:48–54.

    Article  PubMed  Google Scholar 

  20. Gara N, Zhao X, Kleiner DE, et al. Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013;11:303–8.

    Article  CAS  PubMed  Google Scholar 

  21. Malik R, Lai M, Sadiq A, et al. Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. J Gastroenterol Hepatol. 2010;25:1562–8.

    Article  CAS  PubMed  Google Scholar 

  22. Bonder A, Afdhal NH. Biopsy no more; changing the screening and diagnostic algorithm for hepatitis C. Clin Gastroenterol Hepatol. 2013;11:309–10.

    Article  PubMed  Google Scholar 

  23. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199–206.

    Article  PubMed  Google Scholar 

  24. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–9.

    Article  CAS  PubMed  Google Scholar 

  25. Sánchez-Conde M, Montes-Ramírez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat. 2010;17:280–6.

    Article  PubMed  Google Scholar 

  26. Corpechot C, El Naggar A, Poujol-Robert A, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology. 2006;43:1118–24.

    Article  PubMed  Google Scholar 

  27. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–85.

    Article  CAS  PubMed  Google Scholar 

  28. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49:739–44.

    Article  CAS  PubMed  Google Scholar 

  29. de Lédinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–8.

    Article  PubMed  Google Scholar 

  30. Alkhouri N, Sedki E, Alisi A, et al. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int. 2013;33:79–85.

    Article  PubMed  Google Scholar 

  31. Bureau C, Metivier S, Peron JM, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther. 2008;27:1261–8.

    Article  CAS  PubMed  Google Scholar 

  32. Kazemi F, Kettaneh A, N’kontchou G, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol. 2006;45:230–5.

    Article  PubMed  Google Scholar 

  33. Pritchett S, Cardenas A, Manning D, et al. The optimal cut-off for predicting large oesophageal varices using transient elastography is disease specific. J Viral Hepat. 2011;18:e75–80.

    Article  CAS  PubMed  Google Scholar 

  34. Klibansky DA, Mehta SH, Curry M, et al. Transient elastography for predicting clinical outcomes in patients with chronic liver disease. J Viral Hepat. 2012;19:e184–93. Transient elastography is a good tool to stratify high-risk patients with chronic liver disease and can predict risk of liver decompensation.

    Article  CAS  PubMed  Google Scholar 

  35. Cescon M, Colecchia A, Cucchetti A, et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg. 2012;256:706–12.

    Article  PubMed  Google Scholar 

  36. Singh S, Fujii LL, Murad MH, et al. Liver Stiffness Measurements are Associated with Risk of Decompensation, Liver Cancer, and Death in Patients with Chronic Liver Diseases: a Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2013;15:S1542–3565.

    Google Scholar 

  37. Becker L, Salameh W, Sferruzza A, et al. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol. 2009;7:696–701.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Nezam Afdhal has received research support from Merck, Glaxo Smith Kline, Vertex, Gilead, Abbott and BMS. Nezam Afdhal is a consultant/advisory board member for Merck, Gilead, Echosens, Glaxo Smith Kline, Vertex, Novartis, Boehringer Ingelheim, Ligand, Springbank, Medgenics and Kadmon. Afdhal has stock options in Springbank and Medgenics, and is Editor for the Journal of Viral Hepatitis. Alan Bonder has no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis street Suite 8E, Boston, MA, 02215, USA

    Alan Bonder & Nezam Afdhal

Authors
  1. Alan Bonder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nezam Afdhal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nezam Afdhal.

Additional information

This article is part of the Topical Collection on Liver

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonder, A., Afdhal, N. Utilization of FibroScan in Clinical Practice. Curr Gastroenterol Rep 16, 372 (2014). https://doi.org/10.1007/s11894-014-0372-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-014-0372-6

Keywords

Search

Navigation